503A Physician Prescription · Available Now

The peptide stack.
Legally available.

In September 2024, CJC-1295, Ipamorelin, and Selank were removed from FDA Category 2 restriction and can now be legally compounded by 503A pharmacies with a valid physician prescription. On February 27, 2026, HHS Secretary Kennedy announced reclassification of 14 additional peptides — BPC-157, TB-500, AOD-9604, and others — pending formal FDA publication.

WellSpry's biomarker testing creates the clinical documentation that makes every peptide prescription defensible. Your physician reads your labs. The pharmacy compounds patient-specific. You fill the prescription. This is the most compliant peptide model in the market.

Important Notice

Category 1 reclassification is not FDA approval. These are off-label therapeutics requiring a valid physician prescription. Formal FDA Federal Register publication is pending. WellSpry will update this page when the official list is published. Last reviewed: April 2026.

Available Now — 503A Compoundable

These three peptides are already legally compoundable with a physician prescription.

Read the Clinical Primer →
Available Now

CJC-1295

Growth Hormone Releasing Hormone Analogue
Biomarker Trigger
Lean mass loss at 90-day re-test · Testosterone low-normal · Poor sleep
Mechanism
Extends the half-life of GHRH pulses — stimulating pulsatile GH release that supports lean mass, sleep quality, and metabolic rate during caloric restriction.
Protocol
Always paired with Ipamorelin. Introduced at 90-day physician check-in when body composition data justifies it.
CJC-1295 status disputed in some sources due to reported cardiac data. Physician reviews cardiovascular panel before prescribing.
$199/mo (with Ipamorelin)28% at 90-day check-in
Available Now

Ipamorelin

Growth Hormone Secretagogue · Ghrelin Mimetic
Biomarker Trigger
Always paired with CJC-1295 · Solo use when CJC contraindicated
Mechanism
Triggers clean GH release without spiking cortisol or prolactin. The cleanest GH secretagogue available — minimal side effects at therapeutic doses.
Included in CJC-1295 stack · $199/mo28% at 90-day check-in
Available Now

Selank

Anxiolytic · Immune Modulating Heptapeptide
Biomarker Trigger
Elevated AM cortisol · Low DHEA-S · Anxiety reported at month-1 check-in
Mechanism
Modulates GABA-A receptor activity and serotonin metabolism. Clinical analogue of tuftsin — immune modulation plus anxiolytic effect without benzodiazepine mechanism.
Protocol
For patients whose cortisol pattern is blocking fat loss and who report anxiety, sleep disruption, or stress-driven eating. Physician introduces after seeing cortisol AM above 20 μg/dL alongside clinical symptoms.
$129/mo18% at month-2 check-in
Pending Formal FDA Publication

Announced for reclassification February 27, 2026.

Formal Federal Register publication expected Q2–Q3 2026. WellSpry will begin prescribing immediately upon official publication.

Read Full Clinical Primer — All 14 Peptides →

HHS Secretary Kennedy announced these peptides will return to Category 1 on February 27, 2026. The formal FDA publication has not yet been issued as of April 2026. We are monitoring the Federal Register daily.

BPC-157

Body Protection Compound · 15-Amino Acid
Pending
Biomarker Trigger
BIOHM gut score <5 · hs-CRP elevated · GI side effects on GLP-1
Expected Use
Gut lining repair, barrier integrity, tissue repair. Natural clinical follow-on to the Nausea Defense Kit. Most anticipated reclassification for WellSpry.

TB-500

Thymosin Beta-4 Fragment
Pending
Biomarker Trigger
Elevated hs-CRP post-exercise · Joint/tendon issues reported · Active patients
Expected Use
Tissue regeneration, muscle repair, flexibility. For patients training hard to preserve muscle during GLP-1 therapy.

AOD-9604

Anti-Obesity Drug Fragment · hGH 177-191
Pending
Biomarker Trigger
Elevated fasting insulin · HOMA-IR >2.5 · Fat loss plateau despite GLP-1
Expected Use
Targets fat metabolism fragment of hGH without affecting blood sugar or growth. Can be used alongside or instead of GLP-1 for metabolic patients.

KPV

Lys-Pro-Val · Alpha-MSH Fragment
Pending
Biomarker Trigger
BIOHM score <4 · Elevated calprotectin · Gut-dominant inflammation
Expected Use
Anti-inflammatory gut support. Paired with BPC-157 for patients with significant gut pathology.

MOTS-C

Mitochondrial-Derived Peptide
Pending
Biomarker Trigger
Fat loss plateau · Poor exercise tolerance · Low cellular energy markers
Expected Use
Mitochondrial metabolic regulation. For patients whose fat loss has stalled despite protocol adherence — addresses cellular energy efficiency directly.

Semax

ACTH 4-10 Analogue · Neuropeptide
Pending
Biomarker Trigger
Brain fog reported · hs-CRP elevated · Cortisol dysregulation pattern
Expected Use
Cognitive support and neuroprotection. Addresses the gut-brain axis connection — patients with low gut scores and brain fog are natural candidates.

Emideltide (DSIP)

Delta Sleep-Inducing Peptide
Pending
Biomarker Trigger
Elevated AM cortisol · Low testosterone secondary to sleep disruption
Expected Use
Sleep architecture support. Upstream fix for cortisol-driven fat resistance and hormone recovery blockage.

Epitalon

Epithalamin · Tetrapeptide
Pending
Biomarker Trigger
Elevated biological age delta on SiPhox · Longevity track patients · 50+
Expected Use
Longevity and telomere support. Introduced alongside NAD+ at month 4 for patients whose biological age gap exceeds 5 years.

GHK-Cu Injectable

Copper Peptide · Injectable Form
Pending
Biomarker Trigger
Skin assessment at month 2 · Rapid fat loss rate >2lbs/week
Expected Use
Systemic tissue repair. Distinct from WellSpry Skin topical GHK-Cu. Injectable form for patients with significant soft tissue changes or on full longevity track.

Kisspeptin-10

KiSS-1 Derived Peptide · Reproductive Axis
Pending
Biomarker Trigger
Low LH · Low FSH · Hormones segment · Perimenopausal or secondary hypogonadism
Expected Use
Hormone cascade regulation. For patients where LH is low and the upstream signal — not the gonads — is the problem.

Thymosin Alpha-1

Immune Modulating Peptide · 28-Amino Acid
Pending
Biomarker Trigger
Depressed NK markers · Frequent illness · Elevated biological age · Cancer history
Expected Use
Strongest clinical evidence of any peptide on the list. Approved in 35+ countries. For patients whose immune markers show senescence.
How It Works

WellSpry peptide prescribing

01
Test

Your 100+ biomarker panel and gut score create the clinical documentation.

02
Interpret

Your physician reviews the results and identifies which peptides are warranted — if any.

03
Prescribe

Patient-specific prescription sent to our 503A licensed pharmacy network (Belmar Pharma).

04
Fill

You fill the prescription directly. WellSpry never touches the compound.

This is not a questionnaire. This is not a research chemical vendor. This is a board-certified physician reading your actual biomarkers and writing a patient-specific prescription through a licensed 503A compounding pharmacy. The most compliant peptide prescribing model in the market.

Start with Testing — $399 →